35 results on '"Ruiz, E."'
Search Results
2. 502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer
3. 501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
4. 1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses
5. 1456P Impact of early palliative care in quality at the end of life in small cell lung cancer patients
6. 1063P Real-world treatment patterns and outcomes of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) in the US
7. 187P Relationship between immune profile and immunophenotype in early breast cancer
8. LBA10 Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
9. 1481P Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
10. 1088MO A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up
11. 1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
12. 1552P Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
13. 32P PIK3CA exon 9 and 20 mutations in early luminal breast cancer: Case series and review of the literature
14. 516P Outcomes of patients with metastatic anal cancer according to HIV infection: A multicenter study
15. 1094P Demographics, prior therapies and reasons for cemiplimab treatment: Prospective cemiplimAb-rwlc survivorship and epidemiology (C.A.S.E.) study in patients with advanced cutaneous squamous cell carcinoma (CSCC)
16. P-237 Impact of adjuvant chemotherapy in poorly cohesive gastric carcinoma: Experience from the Peruvian National Cancer Institute
17. Differences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR group study
18. Influence of first treatment delay on survival among breast cancer subtypes
19. Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC): A CARESS-CCR group study
20. 594P - Differences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR group study
21. 251P - Influence of first treatment delay on survival among breast cancer subtypes
22. Concordance of KRAS, NRAS and BRAF status between primary colorectal tumors and paired metastasis (mts)
23. Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients
24. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
25. P-243 Clinicopathologic features and survival outcomes of colorectal cancer in young patients: Experience from a cancer institute in Peru
26. 585P - Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC): A CARESS-CCR group study
27. Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625
28. 1584P - Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients
29. 535P - Concordance of KRAS, NRAS and BRAF status between primary colorectal tumors and paired metastasis (mts)
30. 362P - Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625
31. 253P International real-world study of total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC).
32. 196P Epidemiological characteristics and prognosis among patients with fibrolamellar hepatocellular carcinoma: A retrospective cohort in Mexican population.
33. 269P Neutrophil to lymphocyte ratio in locally advanced rectal cancer and prognosis of mortality in Mexican patients.
34. 203P Etiology as a prognostic factor for survival in hepatocellular carcinoma in Latin American population.
35. 91MO Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.